insights_auto
Mtazamo: Thamani itaongezeka kwa asilimia 48.6·Thamani itapungua kwa asilimia 0.0
Nenda kwenye kichupo cha uchanganuzichevron_right
GILD:NASDAQ
Gilead Sciences, Inc
US$ 156.19
arrow_downward
-0.75%(-1.18) Siku 1
US$ 156.84
arrow_upward
+0.42% (+0.65)bedtimeBaada ya saa
Imefungwa: 16 Okt, 16:00:02 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GILD...
Fungua
US$ 157.32
Juu
US$ 157.58
Chini
US$ 155.62
Mtaji wa soko
193.67B
Wastani wa kiasi cha mauzo
5.79M
Kiasi cha mauzo ya hisa
7.77M
Gawio
2.10%
Mgawo wa faida wa kila robo mwaka
US$ 0.82
Tarehe ya kutojumuisha gawio
15 Sep 2026
Juu kwa wiki 52
US$ 160.51
Chini kwa wiki 52
US$ 114.02
EPS
-US$ 2.66
Beta
0.32
Hisa za wawekezaji
1.24B
Idadi ya wafanyakazi
elfu 17
Fungua
US$ 157.32
Juu
US$ 157.58
Chini
US$ 155.62
Mtaji wa soko
193.67B
Wastani wa kiasi cha mauzo
5.79M
Kiasi cha mauzo ya hisa
7.77M
Gawio
2.10%
Mgawo wa faida wa kila robo mwaka
US$ 0.82
Tarehe ya kutojumuisha gawio
15 Sep 2026
Juu kwa wiki 52
US$ 160.51
Chini kwa wiki 52
US$ 114.02
EPS
-US$ 2.66
Beta
0.32
Hisa za wawekezaji
1.24B
Idadi ya wafanyakazi
elfu 17
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Simply Wall Street
·
saa 1 iliyopita
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
saa 3 zilizopita
Gilead chairman & CEO O’Day sells $2.2m in stock
MarketBeat
·
saa 6 zilizopita
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Investing.com Nigeria
·
saa 14 zilizopita
Gilead chief comm & corp aff officer sells $468,660 in GILD shares
Wasifu
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Kuhusu Gilead Sciences, Inc
Afisa Mkuu Mtendaji (CEO)Daniel O'Day
Wafanyakazielfu 17
Lilianzishwa22 Jun 1987
Makao makuuFoster City, California, Marekani
Sekta-
Tovutigilead.com